Tag Archives: Paul Hudson

Sanofi’s Robust Pipeline and Strategic Focus Aim to Lead Immunology Industry

(IN BRIEF) Sanofi is showcasing its ambitious pipeline transformation strategy, which includes a record 12 potential blockbuster opportunities currently under clinical evaluation. Among these, there are nine innovative medicines and vaccines with peak sales potential ranging from €2 to €5 … Read the full press release

Sanofi and Teva Collaborate on Inflammatory Bowel Disease Treatment, TEV’574, in $1.5 Billion Deal

(IN BRIEF) Sanofi and Teva Pharmaceuticals have announced a collaboration to co-develop and co-commercialize TEV’574, a promising asset currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn’s Disease, both forms of inflammatory bowel disease (IBD). … Read the full press release

Global Campaign ‘The Meningitis Flag’ Launched to Raise Meningitis Awareness Ahead of Paris 2024 Paralympic Games

(IN BRIEF) Meningitis Research Foundation, the Confederation of Meningitis Organisations (CoMO), and Sanofi have united to introduce ‘The Meningitis Flag,’ a worldwide campaign aimed at increasing awareness in the fight against meningitis. The campaign, supported by para-athletes including Ellie Challis, … Read the full press release

La exministra francesa de Igualdad de Género se une al consejo asesor DE&I de Sanofi

(NOTICIA EN BREVE) Sanofi ha nombrado a Elisabeth Moreno, exministra francesa de Igualdad de Género, Diversidad e Igualdad de Oportunidades, para su Junta de Diversidad, Equidad e Inclusión (DE&I) para los próximos tres años. El consejo asesor se creó en … Read the full press release

Former French Minister for Gender Equality joins Sanofi’s DE&I advisory council

(IN BRIEF) Sanofi has appointed Elisabeth Moreno, former French Minister for Gender Equality, Diversity and Equal Opportunities, to its Diversity, Equity and Inclusion (DE&I) Board for the next three years. The advisory council was created in 2022 to support Sanofi’s … Read the full press release

Sanofi launches more impactful Corporate Social Responsibility (CSR) strategy

Accelerating projects on access to medicines, support for vulnerable communities, environmental conservation, and diversity and inclusion Creation of Sanofi Global Health, global nonprofit unit to provide 40 of the world’s poorest countries access to 30 essential medicines (PRESS RELEASE) PARIS, 7-Apr-2021 — … Read the full press release

Sanofi gains full global rights to a promising antibody for inflammatory disorders with the acquisition of Kymab

(PRESS RELEASE) PARIS/ CAMBRIDGE, 11-Jan-2021 — /EuropaWire/ — French multinational pharmaceutical company Sanofi to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics. The agreement includes an upfront payment … Read the full press release

Immune-mediated diseases biopharmaceutical Principia Biopharma Inc. acquired by Sanofi for approximately EUR 3.1 billion ($3.68 billion)

Further strengthens core R&D areas of autoimmune and allergic diseases Provides full control of brain-penetrant BTK inhibitor SAR442168 in multiple sclerosis (MS), making commercialization more efficient and eliminating future royalty payments Allows expansion of SAR442168 development program into other central … Read the full press release

COVID-19: Sanofi increases production capacity of hydroxychloroquine; commits to donate 100 million doses

Sanofi to provide Plaquenil® (hydroxychloroquine) wherever possible, while securing appropriate supply levels for current approved indications; The company already increased its production capacity by 50% and is on track to further increase production over the coming months; Ongoing global clinical … Read the full press release